	US 12,258,392 B2
	Anti-IL-25 antibodies and use thereof
Li Guo, Beijing (CN); Tiantian Sun, Beijing (CN); Xiaoxu Qi, Beijing (CN); and Chen Dong, Beijing (CN)
Assigned to Suzhou Kanova Biopharmaceutical Co., Ltd., Jiangsu (CN); and Beijing Kanova Biopharmaceutical Co., Ltd., Beijing (CN)
Appl. No. 17/287,367
Filed by Suzhou Kanova Biopharmaceutical Co., Ltd., Jiangsu (CN); and Beijing Kanova Biopharmaceutical Co., Ltd., Beijing (CN)
PCT Filed Nov. 19, 2018, PCT No. PCT/CN2018/116170 § 371(c)(1), (2) Date Apr. 21, 2021, PCT Pub. No. WO2020/102935, PCT Pub. Date May 28, 2020.
Prior Publication US 2021/0332123 A1, Oct. 28, 2021
Int. Cl. A61K 39/395 (2006.01); A61P 11/06 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/244 (2013.01) [A61K 39/3955 (2013.01); A61P 11/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

13 Claims

1. An anti-interleukin 25 (IL-25) antibody comprising a heavy chain variable region and a light chain variable region, wherein

the heavy chain variable region comprises a complementary determining region 1 (CDR1) having the amino acid sequence GFSLSTSGMGLG (SEQ ID NO: 1), a CDR2 having the amino acid sequence HIWWDDVKHYKPALKS (SEQ ID NO: 2), and a CDR3 having the amino acid sequence MGQLHYYGYDYAMDY (SEQ ID NO: 3); and

the light chain variable region comprises a CDR1 having the amino acid sequence SASSSVSYMY (SEQ ID NO: 4), a CDR2 having the amino acid sequence RTSNLAS (SEQ ID NO: 5), and a CDR3 having the amino acid sequence QLYHSYPPTWT (SEQ ID NO: 6).